INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 245 filers reported holding INTELLIA THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 4.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $2,846,000 | -59.8% | 39,164 | -34.5% | 0.00% | -75.0% |
| Q4 2021 | $7,072,000 | -35.3% | 59,814 | -26.6% | 0.00% | -33.3% |
| Q3 2021 | $10,937,000 | +2.6% | 81,531 | +23.8% | 0.01% | 0.0% |
| Q2 2021 | $10,665,000 | +383.0% | 65,872 | +139.5% | 0.01% | +500.0% |
| Q1 2021 | $2,208,000 | +93.2% | 27,507 | +30.9% | 0.00% | 0.0% |
| Q4 2020 | $1,143,000 | +227.5% | 21,007 | +19.6% | 0.00% | – |
| Q3 2020 | $349,000 | -1.7% | 17,569 | +4.1% | 0.00% | – |
| Q2 2020 | $355,000 | +54.3% | 16,876 | -10.2% | 0.00% | – |
| Q1 2020 | $230,000 | -67.8% | 18,800 | -61.4% | 0.00% | -100.0% |
| Q4 2019 | $714,000 | +303.4% | 48,681 | +267.0% | 0.00% | – |
| Q3 2019 | $177,000 | -14.9% | 13,263 | +4.3% | 0.00% | – |
| Q2 2019 | $208,000 | -22.4% | 12,720 | -18.8% | 0.00% | – |
| Q1 2019 | $268,000 | -35.3% | 15,673 | +8.3% | 0.00% | – |
| Q3 2018 | $414,000 | +25.1% | 14,466 | +19.5% | 0.00% | – |
| Q2 2018 | $331,000 | – | 12,107 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |